Stocktoria
Liquidia Corp LQDA
Liquidia Corp (LQDA) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $158.3M at a -43.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2024-10-16 | Scotiabank | Sector Outperform (init) |
| 2024-10-03 | LifeSci Capital | Outperform (init) |
| 2024-08-23 | HC Wainwright & Co. | Buy (reit) |
| 2024-08-22 | Needham | Buy (reit) |
| 2024-08-20 | BTIG | Buy (main) |
| 2024-08-20 | B of A Securities | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.42 |
| Retained earnings / assets | -1.91 |
| EBIT / assets | -0.157 |
| Equity / liabilities | 0.158 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LQDA | Liquidia Corp | 3/9 | -4.36 | — | +1031.2% |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | 2/9 | — | — | +7.4% |
| MGNX | MACROGENICS INC | 2/9 | -12.89 | — | -0.3% |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | 6/9 | 7.73 | 9.5 | +77.1% |
| KPTI | Karyopharm Therapeutics Inc. | 2/9 | — | — | +0.6% |
| SNDX | Syndax Pharmaceuticals Inc | 1/9 | -7.54 | — | +627.8% |
| PHAT | Phathom Pharmaceuticals, Inc. | 4/9 | — | — | +216.9% |
About Liquidia Corp
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
FAQ
Is LQDA financially healthy?
Liquidia Corp's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does LQDA pay a dividend?
No, Liquidia Corp does not currently pay a dividend.
How profitable is LQDA?
In FY2025, Liquidia Corp had a net margin of -43.5% and a return on equity of -154.0%.
What is the analyst price target for LQDA?
The average Wall-Street price target for Liquidia Corp is $74.25, about 5.8% below the recent price, from 8 analysts (consensus: strong buy).
Is LQDA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Liquidia Corp: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.